Literature DB >> 26109732

The Interferon-Inducible Protein Tetherin Inhibits Hepatitis B Virus Virion Secretion.

Ran Yan1, Xuesen Zhao2, Dawei Cai1, Yuanjie Liu1, Timothy M Block2, Ju-Tao Guo2, Haitao Guo3.   

Abstract

UNLABELLED: Interferon alpha (IFN-α) is an approved medication for chronic hepatitis B therapy. Besides acting as an immunomodulator, IFN-α elicits a pleiotropic antiviral state in hepatitis B virus (HBV)-infected hepatocytes, but whether or not IFN-α impedes the late steps of the HBV life cycle, such as HBV secretion, remains elusive. Here we report that IFN-α treatment of HepAD38 cells with established HBV replication selectively reduced HBV virion release without altering intracellular viral replication or the secretion of HBV subviral particles and nonenveloped capsids. In search of the interferon-stimulated gene(s) that is responsible for the reduction of HBV virion release, we found that tetherin, a broad-spectrum antiviral transmembrane protein that inhibits the egress of a variety of enveloped viruses, was highly induced by IFN-α in HepAD38 cells and in primary human hepatocytes. We further demonstrated that the expression of full-length tetherin, but not the C-terminal glycosylphosphatidylinositol (GPI) anchor-truncated form, inhibited HBV virion egress from HepAD38 cells. In addition, GPI anchor-truncated tetherin exhibited a dominant-negative effect and was incorporated into the liberated virions. We also found colocalization of tetherin and HBV L protein at the intracellular multivesicular body, where the budding of HBV virions takes place. In line with this, electron microscopy demonstrated that HBV virions were tethered in the lumen of the cisterna membrane under tetherin expression. Finally, knockdown of tetherin or overexpression of dominant negative tetherin attenuated the IFN-α-mediated reduction of HBV virion release. Taken together, our study suggests that IFN-α inhibits HBV virion egress from hepatocytes through the induction of tetherin. IMPORTANCE: Tetherin is a host restriction factor that blocks the egress of a variety of enveloped viruses through tethering the budding virions on the cell surface with its membrane anchor domains. Here we report that interferon directly and selectively inhibits the secretion of HBV virions, but not subviral particles or nonenveloped capsids, through the induction of tetherin in hepatocyte-derived cells. The antiviral function of tetherin requires the carboxyl-terminal GPI anchor, while the GPI anchor deletion mutant exhibits dominant negative activity and attaches to liberated HBV virions. Consistent with the fact that HBV is an intracellular budding virus, microscopy analyses demonstrated that the tethering of HBV virions occurs in the intracellular cisterna and that tetherin colocalizes with HBV virions on the multivesicular body, which is the HBV virion budding site. Our study not only expands the antiviral spectrum of tetherin but also sheds light on the mechanisms of interferon-elicited anti-HBV responses.
Copyright © 2015, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26109732      PMCID: PMC4542364          DOI: 10.1128/JVI.00933-15

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  71 in total

Review 1.  Hepatitis B virus biology.

Authors:  C Seeger; W S Mason
Journal:  Microbiol Mol Biol Rev       Date:  2000-03       Impact factor: 11.056

2.  Inducible expression of human hepatitis B virus (HBV) in stably transfected hepatoblastoma cells: a novel system for screening potential inhibitors of HBV replication.

Authors:  S K Ladner; M J Otto; C S Barker; K Zaifert; G H Wang; J T Guo; C Seeger; R W King
Journal:  Antimicrob Agents Chemother       Date:  1997-08       Impact factor: 5.191

3.  Antibody to hepatitis-B-virus core in man.

Authors:  J H Hoofnagle; R J Gerety; L F Barker
Journal:  Lancet       Date:  1973-10-20       Impact factor: 79.321

4.  Antibody to hepatitis B core antigen. A sensitive indicator of hepatitis B virus replication.

Authors:  J H Hoofnagle; R J Gerety; L Y Ni; L F Barker
Journal:  N Engl J Med       Date:  1974-06-13       Impact factor: 91.245

5.  Lambda interferon inhibits hepatitis B and C virus replication.

Authors:  Michael D Robek; Bryan S Boyd; Francis V Chisari
Journal:  J Virol       Date:  2005-03       Impact factor: 5.103

6.  Toll-like receptor signaling inhibits hepatitis B virus replication in vivo.

Authors:  Masanori Isogawa; Michael D Robek; Yoshihiro Furuichi; Francis V Chisari
Journal:  J Virol       Date:  2005-06       Impact factor: 5.103

7.  Transcriptional and posttranscriptional control of hepatitis B virus gene expression.

Authors:  Susan L Uprichard; Stefan F Wieland; Alana Althage; Francis V Chisari
Journal:  Proc Natl Acad Sci U S A       Date:  2003-01-27       Impact factor: 11.205

8.  Ultrastructural analysis of hepatitis B virus in HepG2-transfected cells with special emphasis on subviral filament morphogenesis.

Authors:  P Roingeard; C Sureau
Journal:  Hepatology       Date:  1998-10       Impact factor: 17.425

9.  BST2/CD317 counteracts human coronavirus 229E productive infection by tethering virions at the cell surface.

Authors:  Shiu-Mei Wang; Kuo-Jung Huang; Chin-Tien Wang
Journal:  Virology       Date:  2013-12-15       Impact factor: 3.616

10.  Alpha-interferon suppresses hepadnavirus transcription by altering epigenetic modification of cccDNA minichromosomes.

Authors:  Fei Liu; Matthew Campagna; Yonghe Qi; Xuesen Zhao; Fang Guo; Chunxiao Xu; Sichen Li; Wenhui Li; Timothy M Block; Jinhong Chang; Ju-Tao Guo
Journal:  PLoS Pathog       Date:  2013-09-12       Impact factor: 6.823

View more
  44 in total

1.  Detection of Hepatitis B Virus Particles Released from Cultured Cells by Particle Gel Assay.

Authors:  Ran Yan; Dawei Cai; Yuanjie Liu; Haitao Guo
Journal:  Methods Mol Biol       Date:  2017

2.  Hepatitis B Virus Subverts the Autophagy Elongation Complex Atg5-12/16L1 and Does Not Require Atg8/LC3 Lipidation for Viral Maturation.

Authors:  Tatjana Döring; Lisa Zeyen; Christina Bartusch; Reinhild Prange
Journal:  J Virol       Date:  2018-03-14       Impact factor: 5.103

Review 3.  Modulators of innate immunity as novel therapeutics for treatment of chronic hepatitis B.

Authors:  Aleksei Suslov; Stefan Wieland; Stephan Menne
Journal:  Curr Opin Virol       Date:  2018-02-20       Impact factor: 7.090

4.  Interferon Alpha Induces Multiple Cellular Proteins That Coordinately Suppress Hepadnaviral Covalently Closed Circular DNA Transcription.

Authors:  Junjun Cheng; Qiong Zhao; Yan Zhou; Liudi Tang; Muhammad Sheraz; Jinhong Chang; Ju-Tao Guo
Journal:  J Virol       Date:  2020-08-17       Impact factor: 5.103

5.  Naturally occurring core protein mutations compensate for the reduced replication fitness of a lamivudine-resistant HBV isolate.

Authors:  Yongmei Zhang; Hu Zhang; Junjie Zhang; Jiming Zhang; Haitao Guo
Journal:  Antiviral Res       Date:  2019-03-19       Impact factor: 5.970

6.  Establishment of an inducible HBV stable cell line that expresses cccDNA-dependent epitope-tagged HBeAg for screening of cccDNA modulators.

Authors:  Dawei Cai; Xiaohe Wang; Ran Yan; Richeng Mao; Yuanjie Liu; Changhua Ji; Andrea Cuconati; Haitao Guo
Journal:  Antiviral Res       Date:  2016-05-13       Impact factor: 5.970

7.  Early Vertebrate Evolution of the Host Restriction Factor Tetherin.

Authors:  Elena Heusinger; Silvia F Kluge; Frank Kirchhoff; Daniel Sauter
Journal:  J Virol       Date:  2015-09-23       Impact factor: 5.103

8.  Type I IFN Sensing by cDCs and CD4+ T Cell Help Are Both Requisite for Cross-Priming of AAV Capsid-Specific CD8+ T Cells.

Authors:  Jamie L Shirley; Geoffrey D Keeler; Alexandra Sherman; Irene Zolotukhin; David M Markusic; Brad E Hoffman; Laurence M Morel; Mark A Wallet; Cox Terhorst; Roland W Herzog
Journal:  Mol Ther       Date:  2019-11-15       Impact factor: 11.454

9.  A novel pyridazinone derivative inhibits hepatitis B virus replication by inducing genome-free capsid formation.

Authors:  Ya-Juan Wang; Dong Lu; Yi-Bin Xu; Wei-Qiang Xing; Xian-Kun Tong; Gui-Feng Wang; Chun-Lan Feng; Pei-Lan He; Li Yang; Wei Tang; You-Hong Hu; Jian-Ping Zuo
Journal:  Antimicrob Agents Chemother       Date:  2015-09-08       Impact factor: 5.191

Review 10.  Development of Direct-acting Antiviral and Host-targeting Agents for Treatment of Hepatitis B Virus Infection.

Authors:  Yuchen Xia; T Jake Liang
Journal:  Gastroenterology       Date:  2018-09-19       Impact factor: 22.682

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.